达雷妥尤单抗联合泊马度胺和地塞米松治疗复发和/或难治性多发性骨髓瘤
该研究评估达雷妥尤单抗联合泊马度胺和地塞米松(pom-dex)用于既往至少2线治疗且末次治疗难治的复发/难治性多发性骨髓瘤患者,主要终点为安全性。103例患者总体缓解率60%,中位无进展生存期8.8个月,中位总生存期17.5个月,安全性除输注相关反应和中性粒细胞减少增加外与pom-dex单药相似。
要点
- 达雷妥尤单抗联合pom-dex在重度经治患者中总体缓解率60%,双难治患者为58%。
- 常见≥3级不良事件为中性粒细胞减少78%、贫血28%、白细胞减少24%。
- 中位随访13.1个月,中位无进展生存期8.8个月,中位总生存期17.5个月。
核心结论
- 除中性粒细胞减少增加外,达雷妥尤单抗联合pom-dex的安全性特征与各单药治疗一致。
- 在重度经治患者中观察到深度、持久的缓解。
研究设计与样本
- 研究纳入既往至少2线治疗且对末次治疗难治的复发/难治性多发性骨髓瘤患者,共103例。
- 患者接受达雷妥尤单抗16 mg/kg按推荐给药方案、泊马度胺4 mg每日一次每28天周期用21天、地塞米松40 mg每周一次。
- 主要终点为安全性,总体缓解率和下一代测序检测的微小残留病为次要终点。
- 研究注册号为NCT01998971。
主要发现
- 患者既往治疗中位4线(范围1-13),76%接受过至少3线治疗。
- 总体缓解率为60%,双难治患者为58%。
- 达雷妥尤单抗特异性输注相关反应发生率为50%。
- 常见≥3级不良事件为中性粒细胞减少78%、贫血28%、白细胞减少24%。
- 在达到完全缓解或更好的患者中,29%在10^-5阈值下微小残留病阴性。
关键数值与推荐
- 62例缓解者的中位缓解持续时间不可估计(95%CI 13.6-不可估计)。
- 中位随访13.1个月时,中位无进展生存期为8.8个月(95%CI 4.6-15.4),中位总生存期为17.5个月(95%CI 13.3-不可估计)。
- 估计12个月生存率为66%(95%CI 55.6-74.8)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Daratumumab plus pomalidomide and dexamethasone (pom-dex) was evaluated in patients with relapsed/refractory multiple myeloma with ≥2 prior lines of therapy who were refractory to their last treatment. Patients received daratumumab 16 mg/kg at the recommended dosing schedule, pomalidomide 4 mg daily for 21 days of each 28-day cycle, and dexamethasone 40 mg weekly. Safety was the primary end point. Overall response rate (ORR) and minimal residual disease (MRD) by next-generation sequencing were secondary end points. Patients (N = 103) received a median (range) of 4 (1-13) prior therapies; 76% received ≥3 prior therapies. The safety profile of daratumumab plus pom-dex was similar to that of pom-dex alone, with the exception of daratumumab-specific infusion-related reactions (50%) and a higher incidence of neutropenia, although without an increase in infection rate. Common grade ≥3 adverse events were neutropenia (78%), anemia (28%), and leukopenia (24%). ORR was 60% and was generally consistent across subgroups (58% in double-refractory patients). Among patients with a complete response or better, 29% were MRD negative at a threshold of 10-5 Among the 62 responders, median duration of response was not estimable (NE; 95% confidence interval [CI], 13.6-NE). At a median follow-up of 13.1 months, the median progression-free survival was 8.8 (95% CI, 4.6-15.4) months and median overall survival was 17.5 (95% CI, 13.3-NE) months. The estimated 12-month survival rate was 66% (95% CI, 55.6-74.8). Aside from increased neutropenia, the safety profile of daratumumab plus pom-dex was consistent with that of the individual therapies. Deep, durable responses were observed in heavily treated patients. The study was registered at www.clinicaltrials.gov as #NCT01998971.
引用
- Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017. PMID: 28637662. doi:10.1182/blood-2017-05-785246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。